Making Biologic Treatments More Affordable
Many conventional drugs are made up of small chemical compounds. Other well-known medicines, called biologics, are complex substances derived from living organisms. Several biologics represent the cutting edge of medical science and have become the standard of care for various devastating and debilitating diseases, such as cancer and autoimmune diseases. However, while reliance on these important treatment options has continued to increase, access is being restricted due to their high cost. A biosimilar is a product that is highly similar to and has no clinically meaningful differences from an existing approved biologic product. There is already evidence that biosimilars have helped to make biological treatments more affordable in parts of the world.
Mylan has one of the most comprehensive and diverse biosimilar programs in the industry, with 20 biosimilar and insulin analog products on the market or in our global pipeline focused on the areas of oncology, immunology, endocrinology, dermatology and ophthalmology. Our program is designed to serve multiple markets, including low- and middle-income countries.